Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A

Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A

SSZSE:301096
38.64
CNY
+0.86
(+2.28%)
-1.65EPS
5.38BMarket Cap
Apr 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.22
0.85
1.68
2.04
0.43
1.34
2.11
2.56
4.62
5.63
9.39
7.45
6.23
5.7
Basic EPS, GAAP
-0.07
-0.23
0.51
0.27
-0.12
0.18
0.6
0.71
1.37
1.8
2.51
-0.49
-0.83
-1.64
Free Cash Flow per Basic Share
-0.01
-0.26
-0.01
-0.63
-0.34
0.42
-0.48
-2.48
-1.27
-3.08
-5.52
-5.49
-2.32
- -
Dividend per Share
- -
- -
- -
0.02
0.08
0.02
0.19
0.11
0.12
0.62
0.86
0.45
0.19
0.2
Book Value per Share
-0.17
-0.15
0.95
1.18
1.95
1.64
3.43
4.19
21.43
22.95
24.64
23.61
22.79
22.21
Tangible Book Value per Share
-0.17
-0.15
0.95
1.18
1.78
1.61
2.73
3.42
20.87
22.19
23.8
22.76
21.96
21.41
Basic Weighted Avg Shares
14
7
10
12
59
61
74
81
81
108
108
108
109
108
Sales/Revenue/Turnover
3
6
16
24
26
82
156
207
374
607
1,017
802
678
618
Operating Margin (%)
-29.57
-29.22
37.59
13.59
-31.08
12.98
32.42
31.77
33.43
26.48
29.28
2.05
-3.8
-18.47
Depreciation Expense
- -
1
1
2
5
10
13
17
35
64
91
146
158
- -
Net Income, GAAP
-1
-2
5
3
-7
11
44
57
111
194
272
-53
-90
-178
Effective Tax Rate (%)
- -
- -
17.96
10.76
- -
5.05
11.76
12.19
6.71
- -
8
- -
- -
- -
Profit Margin (%)
-30.09
-27.18
30.44
13.21
-27.84
13.45
28.38
27.7
29.68
31.97
26.73
-6.58
-13.33
-28.83
Working Capital
-7
-8
2
-2
-18
42
158
117
1,753
1,319
762
776
632
736
LT Debt
- -
- -
- -
- -
- -
- -
- -
155
49
- -
1
247
192
286
Total Equity
-2
-2
13
17
27
75
279
340
2,318
2,482
2,684
2,579
2,489
2,427
Return on Invested Capital (%)
- -
- -
85.37
10.06
- -
18.64
25.45
14.67
7.14
- -
9.87
- -
- -
- -
Return on Capital (%)
- -
- -
86.93
19.29
- -
24.28
24.77
15.26
7.36
- -
10.04
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
21.56
-33.21
21.91
25.19
18.58
8.36
8.09
10.53
-2
-3.57
-7.11

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
698
689
660
LT Borrowings
310
285
286
LT Finance Leases
3
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
109
109
109
Market Capitalization
5,553
6,247
5,385

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,698
1,663
1,629
Cash, Cash Equivalents & STI
457
395
344
Accounts Receivable, Net
519
525
559
Inventories
180
195
193
Total Current Liabilities
906
902
892
Payables & Accruals
- -
- -
- -
ST Debt
698
689
660
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
114.89%
118.09%
-3.51%
Free Cash Flow
609.06%
39.07%
-57.26%
Net Income, GAAP
-12.6%
32.07%
71.39%
Sales/Revenue/Turnover
57.2%
34.75%
-15.45%
Total Cash Common Dividend
440.28%
101.48%
-57.92%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
216
309
196
80
802
2025
129
204
- -
168
678
2026
160
144
145
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.46
0.78
0.07
-1.79
-0.49
2025
-0.24
0.27
- -
-0.89
-0.83
2026
0.12
-0.1
-0.77
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.34
0.04
0.04
0.45
2025
0.04
0.05
- -
0.04
0.19
2026
0.05
0.05
0.05
- -
- -

Company Description

CEO
Jin Fang Lou
Full Time Employees
1,412
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Hangzhou China
IPO Date
Dec 20, 2021
Business
Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. is a comprehensive pharmaceutical contract research organization and contract development and manufacturing organization providing integrated drug discovery, formulation development, clinical research, and commercialization services to domestic and international pharmaceutical and biotechnology enterprises. Founded in 2011 and headquartered in Hangzhou, Zhejiang Province, China, the company operates modern research and development laboratories, bioanalytical testing facilities, and Good Manufacturing Practice compliant production sites across China. Hangzhou Bio-Sincerity Pharma-Tech structures its business into four principal operational divisions: Pharmaceutical Research and Development Services, Clinical Operations and Bioanalytical Services, CDMO Manufacturing Services, and Proprietary Technology Transfer and Commercialization. The company's core products and service offerings include preclinical pharmaceutical research, encompassing active pharmaceutical ingredient chemical synthesis, synthetic process optimization, formulation design, analytical chemistry, impurity characterization, and stability testing; clinical trial and bioequivalence services, covering Phase I to IV clinical trial management, medical writing, trial monitoring, regulatory filing, data management, biostatistical analysis, and high-throughput bioanalytical pharmacokinetic and pharmacodynamic assays; generic drug consistency evaluation services, comprising comparative dissolution profile studies, pharmaceutical equivalence testing, and regulatory submission documentation; CDMO pilot and commercial production, providing pilot-scale formulation manufacturing, sterile injectable preparation, oral solid dosage production, and commercial active pharmaceutical ingredient manufacturing through dedicated subsidiaries including Zhejiang Saimo Pharmaceutical Co., Ltd.; and proprietary drug research and technology transfer, involving the independent development, out-licensing, and collaborative commercialization of complex generic formulations, modified-release pharmaceuticals, and innovative small molecules with associated milestone and royalty-sharing rights. In recent developments, the company has expanded its integrated CDMO operational capacity through the ramp-up of commercial-scale GMP manufacturing bases, augmented its proprietary research pipeline with an increased focus on complex formulation delivery systems, specialized inhalation therapies, and peptide platforms, strengthened strategic co-development partnerships with major domestic pharmaceutical manufacturers, and upgraded its high-throughput bioanalysis and automated clinical data infrastructure to support cross-regional drug approvals.